Although phase I/II clinical trial has shown that Wilms tumor 1 (WT1)–targeted DC vaccine was a potential treatment in advanced cancer including GC, only three GC patients were included in the enrolled patients and only one GC patient was effective (161). This evidence concerns the gene WT1 and gastric cancer.